Sebastian Gensior

Terray Therapeutics has assembled what may be the largest proprietary chemistry dataset in drug discovery—13+ billion target-molecule binding measurements, growing at 1 billion per quarter. The Los Angeles-based company has raised over $200 million.

The Volume Trap: Why Diagnostic Royalties Don't Compound Royalty financing has become a cornerstone of life sciences capital formation, with biopharma royalty deals totaling $29.4 billion from 2020-2024. Yet the molecular diagnostics industry—now generating over $20 billion annually—remains almost entirely absent from this market.

Biotech ETFs surge in 2025 as sector emerges from nuclear funding winter. XBI +37%, ARKG +43%, IBB +30%—all crushing the S&P 500. Big Pharma's $176B patent cliff drives M&A frenzy with 100%+ premiums. Fund flows turn positive for first time since 2021. Is the biotech winter finally over?

Royalty financing can be structured as a “true sale” (outright transfer) or a secured loan backed by royalties. True sales often reduce bankruptcy risk and can bring legal/financial advantages; loan-like structures may leave the buyer exposed if the seller faces distress.

The week's transactions tell a clear story: China-origin assets now command 32% of global licensing deal value, up from 21% just two years ago. This structural shift reflects years of R&D investment now yielding differentiated clinical-stage assets that global pharma cannot replicate internally. Antibody-

Biotech valuation hinges on a small number of binary clinical events. A Phase 3 readout. An FDA approval letter. A manufacturing inspection that either passes or doesn't. These go/no-go moments create the fundamental tension in pharmaceutical M&A: buyers and sellers often agree on everything

In my November 25 post, I discussed "Royalties as a Credit Derivative," exploring how creative financing can extend a biotech's runway without diluting equity. Oberland Capital is the real-world practitioner of that theory – a specialist fund that doesn't just bet on biotech outcomes,

Dayra Therapeutics is a Toronto-based biotech company developing oral macrocyclic peptide drugs for immunological diseases. The company launched in November 2025 with approximately $70 million in committed funding, comprising a $50 million upfront payment from Biogen and a $20 million equity commitment from Versant Ventures. The company emerged from

The pharmaceutical royalty market has grown at a 45% CAGR since 2018, reaching over $6 billion in annual transaction volume—yet sophisticated investors operate almost entirely without the insurance and reinsurance tools that other asset classes take for granted. This gap creates both significant risk management challenges and potential opportunities

A stage-by-stage decision framework for evaluating synthetic royalties, royalty monetization, and alternatives in the $29 billion royalty financing market Pharmaceutical royalty financing has transformed from a niche instrument into a $29.4 billion market (2020–2024), more than double the preceding five years. But the critical question isn&